comparative evaluation of enoxaparin and rivaroxaban treatment outcomes in cancer patients with venous thromboembolism: a prospective cohort study

Introduction: the purpose of this study is to assess and compare the efficacy of rivaroxaban and enoxaparin in the management of venous thromboembolism (vte) in cancer patients, as well as to evaluate potential risk factors associated with vte recurrence. materials and methods: a retrospective cohort study design was employed, analyzing 402 patients above 18 years of age who were diagnosed with cancer and treated for vte at imam reza and ghaem hospitals between 2023 and 2024. exclusion criteria were also set, and treatment regimens were detailed for both drugs. the analysis was conducted using chi-square tests, independent t-tests, and logistic regression. results: the data revealed that rivaroxaban was used more frequently than enoxaparin, although the mean age was higher in the enoxaparin group. no significant difference was observed in terms of vte recurrence between the two drugs. conclusion: the study concludes that rivaroxaban and enoxaparin are both effective in treating vte in cancer patients. the selection of medication may depend on the specific characteristics of each patient.